Danish Healthtech Stock News

CPSE:FLS
CPSE:FLSMachinery

FLSmidth Repeat Contracts Highlight MissionZero Role In Mining Valuation Story

FLSmidth (CPSE:FLS) has secured significant repeat contracts for a major Banded Hematite Quartzite beneficiation project. The orders cover industry leading technologies, including what is described as the world's largest High Pressure Grinding Roll and several large scale stirred media mills. The equipment package is aligned with FLSmidth's MissionZero ambition, aiming to support more sustainable mining operations. The latest awards add substantial contracted work for the coming years for...
CPSE:JYSK
CPSE:JYSKBanks

Jyske Bank Q1 Cost To Income Setback Tests Bullish Efficiency Narrative

Jyske Bank (CPSE:JYSK) Q1 2026 earnings: softer top line, leaner margins Jyske Bank (CPSE:JYSK) opened 2026 with Q1 revenue of DKK3.1b and net income of DKK984m, translating into basic EPS of DKK16.94. This provides a clear snapshot of how the bank is starting the year. Over the past year, the bank has seen revenue move from DKK14.4b to DKK14.2b on a trailing 12 month basis, while trailing EPS shifted from DKK85.49 to DKK83.22. This gives a sense of how the income statement has been trending...
CPSE:AMBU B
CPSE:AMBU BMedical Equipment

Ambu (CPSE:AMBU B) Margin Expansion Outpaces Revenue Growth And Tests Bullish Earnings Narrative

Ambu (CPSE:AMBU B) has just reported Q2 2026 revenue of DKK1.6b and basic EPS of DKK0.46, with trailing twelve month revenue at DKK6.1b and EPS at DKK1.79 setting the backdrop for the latest quarter. Over recent quarters the company has seen revenue move from DKK1.55b in Q2 2025 to DKK1.57b in Q2 2026, while quarterly EPS has ranged between DKK0.43 and DKK0.71 over the same period. This gives investors a clear view of how earnings are tracking against the top line. With a trailing net profit...
CPSE:ZEAL
CPSE:ZEALBiotechs

Assessing Zealand Pharma (CPSE:ZEAL) Valuation After Recent Share Price Weakness And Undervaluation Claims

How Zealand Pharma Stock Has Been Performing Zealand Pharma (CPSE:ZEAL) has drawn renewed investor attention after a mixed stretch, with the stock showing gains over the past month but negative moves over the past 3 months, year to date, and the past year. Over the past month, the share price return stands at about 5.8%, while the past 3 months show a decline of around 21.1%. Year to date, the stock is down roughly 31.5%, and the past year reflects a total return decline of about...
CPSE:VWS
CPSE:VWSElectrical

Vestas Wind Systems (CPSE:VWS) Margin Recovery To 4.4% Reinforces Earnings Growth Narrative

Vestas Wind Systems (CPSE:VWS) opened 2026 with Q1 revenue of €3.97b and basic EPS of €0.08, setting the tone for how the year is starting after a busy 2025. Over recent quarters, the company has seen quarterly revenue move from €3.47b and EPS of roughly €0.00 in Q1 2025 to €6.27b and €0.44 in Q4 2025, with trailing twelve month EPS at €0.83 on €19.32b of revenue. This gives investors a clear read on how volumes and profitability are feeding through to the income line as net margins sit at...
CPSE:NOVO B
CPSE:NOVO BPharmaceuticals

Novo Nordisk (CPSE:NOVO B) Q1 Margin Surge Challenges Cautious Earnings Narratives

Novo Nordisk (CPSE:NOVO B) opened 2026 with Q1 revenue of DKK 96.8b and basic EPS of DKK 10.93, while the trailing twelve months show revenue of DKK 327.8b and EPS of DKK 27.44. Over the past year, revenue has moved from DKK 290.4b to DKK 327.8b and EPS from DKK 22.67 to DKK 27.44 on a trailing basis. This sets a clear benchmark for how current profitability aligns with investor expectations. With net margin running at 37.2% versus 34.5% a year earlier, the latest results put the focus...
CPSE:PNDORA
CPSE:PNDORALuxury

Pandora (CPSE:PNDORA) Q1 Net Margin Compression Challenges Bullish Profitability Narrative

Pandora (CPSE:PNDORA) opened 2026 with Q1 revenue of DKK 7.1b and basic EPS of DKK 12.6, alongside net income of DKK 942m, setting a clear marker for how the year is starting after a busy 2025. Over recent quarters the company has seen revenue move between DKK 6.3b and DKK 11.9b, while basic EPS has ranged from DKK 6.3 to DKK 37. This gives you a broad view of how the top and bottom line have tracked through different trading periods. With a trailing net profit margin of 15.7%, the latest...
CPSE:NETC
CPSE:NETCIT

Netcompany Group (CPSE:NETC) Q1 Margin Compression Tests Bullish Re‑Rating Narratives

Q1 2026 results set up a mixed but interesting picture Netcompany Group (CPSE:NETC) has kicked off 2026 with Q1 revenue of DKK 2.4b and basic EPS of DKK 3.15, putting fresh numbers on the table for a stock trading around DKK 356.8. Over the past six reported quarters, revenue has moved from DKK 1.7b in Q4 2024 to DKK 2.4b in Q1 2026. Quarterly EPS has ranged from a loss of DKK 1.44 in Q3 2025 to DKK 3.21 in Q4 2025 and DKK 3.15 in the latest quarter, setting up a results season where...
CPSE:DSV
CPSE:DSVLogistics

A Look At DSV (CPSE:DSV) Valuation After Mixed Q1 Results And Reaffirmed 2026 EBIT Guidance

DSV (CPSE:DSV) just opened 2026 with first quarter results that paired higher sales with lower profitability, while management kept full year EBIT guidance intact, including expected Schenker related synergies. See our latest analysis for DSV. The stock is trading at DKK1,504.5, with a 1 day share price return of 3.47% but a 90 day share price return reflecting an 18.37% decline. Meanwhile, the 1 year total shareholder return of 4.36% and 3 year total shareholder return of 16.58% point to...
CPSE:ALMB
CPSE:ALMBInsurance

Is Alm. Brand (CPSE:ALMB) Pricing In Its Excess Returns Potential At Kr.15.26?

This article examines whether Alm. Brand is attractively priced or if the current share price already reflects most of its potential, by breaking down what the current valuation signals may indicate about the stock. The share price recently closed at kr.15.26, with returns of 1.7% over the past week, a 3.6% decline over the last month, and a 1.4% gain over the past year, alongside a 42.0% three year and 13.2% five year return profile. These moves sit against a backdrop of ongoing coverage...
CPSE:RILBA
CPSE:RILBABanks

A Look At Ringkjøbing Landbobank’s Valuation After Recent Share Price Moves

Ringkjøbing Landbobank stock snapshot after recent moves Ringkjøbing Landbobank (CPSE:RILBA) has attracted fresh attention after recent price moves, with the stock showing mixed short term performance alongside longer term total returns and measurable annual growth in revenue and net income. See our latest analysis for Ringkjøbing Landbobank. Recent trading has been relatively steady, with a 1 day share price return of 1.09% and a 7 day share price return of 1.15%. The 1 year total...
CPSE:DFDS
CPSE:DFDSShipping

DFDS Q1 Loss Narrows Yet Keeps Turnaround Narratives Under Pressure

DFDS Q1 2026 results set the tone for a profit-focused turnaround story DFDS (CPSE:DFDS) has opened 2026 with Q1 revenue of DKK 7.4b and a basic EPS loss of DKK 3.29, alongside a trailing twelve month net loss of DKK 276m and EPS of DKK 5.11 in the red, which keeps the focus squarely on the path back to profitability. Over recent quarters the company has seen revenue move between DKK 7.2b and DKK 8.3b, while EPS has swung from a loss of DKK 6.09 to a profit of DKK 5.13 before reverting to...
CPSE:NTG
CPSE:NTGTransportation

NTG Nordic Transport Group Q1 Margin Compression Tests Bullish Growth Narrative

Q1 2026 results set the tone for NTG Nordic Transport Group (CPSE:NTG) NTG Nordic Transport Group (CPSE:NTG) opened 2026 with Q1 revenue of DKK 2,983 million and basic EPS of DKK 2.62, framing the latest quarterly read alongside a trailing twelve month EPS of DKK 10.14 on revenue of DKK 11.67 billion. Over the past year, the company has seen revenue move from DKK 9.35 billion in the trailing twelve months to Q4 2024 to DKK 11.67 billion by Q1 2026, while trailing EPS shifted from DKK 13.94 to...
CPSE:MAERSK B
CPSE:MAERSK BShipping

Maersk Fairfax Transit Highlights Geopolitical Risk And Valuation Debate

Maersk's U.S.-flagged vessel Fairfax completed a safe transit of the Strait of Hormuz after being stuck in the Persian Gulf for months. The passage, supported by military escort, marks a key operational development for A.P. Møller Mærsk (CPSE:MAERSK B) in a high-risk shipping corridor. This update adds new detail to the company’s recent experience with Middle East route disruptions and security challenges. A.P. Møller Mærsk, listed as CPSE:MAERSK B, is a global container shipping and...
CPSE:TRIFOR
CPSE:TRIFORIT

Trifork Group (CPSE:TRIFOR) Margin Compression Challenges Bullish Earnings Recovery Narrative

Trifork Group (CPSE:TRIFOR) has just posted its Q1 2026 scorecard, with recent quarterly context showing Q4 2025 revenue of €59.1 million, basic EPS of €0.44 and net income of €8.5 million. The trailing twelve months to Q4 2025 came in at €221.2 million of revenue, basic EPS of €0.53 and net income of €10.3 million. Over the past few reported quarters, revenue has moved between €47.2 million and €59.1 million, with basic EPS ranging from a slight loss of €0.01 to €0.63 and net income...
CPSE:NSIS B
CPSE:NSIS BChemicals

Novozymes (CPSE:NSIS B) Margin Jump To 14% Tests Growth Narrative Ahead Of Q1 2026

Novozymes (CPSE:NSIS B) has opened Q1 2026 earnings season with recent quarterly revenue between €981.4 million and €1.08 billion over the past six reported periods, while quarterly EPS ranged from €0.26 to €0.40, and trailing twelve month EPS most recently sat at €1.25 on €4.16 billion of revenue. Over that stretch, revenue has moved from €3.83 billion and EPS of €1.10 on a trailing basis in Q4 2024 to €4.16 billion and EPS of €1.25 by Q4 2025. With trailing net profit margin at 14% compared...
CPSE:ROCK B
CPSE:ROCK BBuilding

Assessing Rockwool (CPSE:ROCK B) Valuation After A Year Of Mixed Share Performance

Rockwool stock snapshot after recent performance Rockwool (CPSE:ROCK B) has drawn investor attention after a year of mixed share performance, with the stock showing a return of about 0.6% over the past day but a 39% decline over the past year. See our latest analysis for Rockwool. With the share price at DKK180.8, Rockwool’s recent 1 day share price return of 0.56% sits against a weaker trend, including a 90 day share price return of a 21% decline and a 1 year total shareholder return of a...
CPSE:NOVO B
CPSE:NOVO BPharmaceuticals

Is Novo Nordisk (CPSE:NOVO B) Attractive After Recent Share Price Rebound And Valuation Gap?

If you are trying to figure out whether Novo Nordisk is attractively priced or not, the stock's recent moves and current valuation checks give you a lot to work with. The share price recently closed at kr.286.25, with a 7 day return of 8.0%, 30 day return of 20.8%, a year to date return showing a 13.3% decline, and a 1 year return showing a 32.1% decline, which may suggest changing views on both opportunity and risk. Recent headlines have continued to spotlight Novo Nordisk's role in...
CPSE:DNORD
CPSE:DNORDShipping

Assessing Dampskibsselskabet Norden’s Valuation After Upgraded 2026 Profit Guidance

Dampskibsselskabet Norden (CPSE:DNORD) lifted its 2026 full year net profit guidance to a range of US$70 million to US$140 million, up from US$30 million to US$100 million, a shift many investors will scrutinize closely. See our latest analysis for Dampskibsselskabet Norden. The upgraded 2026 profit guidance comes as the stock trades at DKK316.0, with a 90-day share price return of 26.91% and a 1-year total shareholder return of 70.98%, suggesting momentum has been building over both shorter...
CPSE:ALK B
CPSE:ALK BPharmaceuticals

ALK Abelló (CPSE:ALK B) Q1 EPS Jump Tests Premium Valuation Narrative

ALK-Abelló (CPSE:ALK B) has opened 2026 with Q1 revenue of DKK 1.8b and basic EPS of DKK 2, set against trailing twelve month revenue of DKK 6.6b and EPS of about DKK 5.8 as the company builds on a year in which earnings grew 36.6%. Over the past year, revenue has moved from DKK 5.5b to DKK 6.6b and trailing EPS has progressed from roughly DKK 3.7 to DKK 5.8, while net profit margin has lifted from 16.4% to 19.5%. This gives the latest quarter a firm profitability backdrop for investors...
CPSE:FLS
CPSE:FLSMachinery

A Look At FLSmidth (CPSE:FLS) Valuation After Recent Share Price Weakness

Recent share performance and business profile FLSmidth (CPSE:FLS) has drawn investor attention after a period of weaker share performance, with the stock showing declines over the past week, month and past 3 months despite a positive 1 year total return. The Copenhagen based mining equipment and services company reports annual revenue of DKK 14,612.0 million and net income of DKK 706.0 million, with operations spread across service, product and pumps, cyclones & valves segments worldwide. See...
CPSE:EMBLA
CPSE:EMBLAMedical Equipment

A Look At Embla Medical hf (CPSE:EMBLA) Valuation After Q1 2026 Earnings Growth

Q1 earnings highlight Embla Medical hf (CPSE:EMBLA) performance shift Embla Medical hf (CPSE:EMBLA) has drawn fresh attention after reporting first quarter 2026 earnings, with sales of US$232.4 million and net income of US$14.46 million compared with the same period a year earlier. See our latest analysis for Embla Medical hf. At a share price of DKK27.25, Embla Medical hf has seen a 1-day share price return of 1.87%, while its 90-day share price return of 14.04% and 1-year total shareholder...
CPSE:NETC
CPSE:NETCIT

Coloplast And 2 Other European Stocks That Might Be Priced Below Their Estimated Value

As the pan-European STOXX Europe 600 Index ended the week broadly flat amid stalled geopolitical negotiations and fluctuating oil prices, investors are keenly observing potential opportunities in undervalued stocks. In this context, identifying stocks that might be priced below their estimated value can be crucial for those looking to capitalize on positive earnings momentum despite broader economic uncertainties.